-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 19, 2021, Janssen, a subsidiary of Johnson & Johnson, announced the preliminary data of the Phase 1 clinical trial CHRYSALIS
.
The trial aims to evaluate its EGFR/MET bispecific antibody therapy Rybrevant (amivantamab-vmjw) for the treatment of non-small cell lung cancer (NSCLC) with mutations in exon 14 of the mesenchymal-epithelial transition (MET) gene (METex14) ) Patients
Rybrevant is a humanized EGFR/MET bispecific antibody
.
It has multiple anti-cancer mechanisms.
In China, this bispecific antibody therapy has been included as a breakthrough treatment product by the National Food and Drug Administration (NMPA) of China.
A number of clinical trials are currently underway in China, including a combination with the third-generation EGFR tyrosine kinase inhibitor lazertinib Used as the first-line treatment for locally advanced or metastatic non-small cell lung cancer with EGFR mutations
.
NSCLC accounts for 80%-85% of all lung cancers, and about 3% of patients have METex14 mutations
.
This mutation causes excessive activation of the MET receptor and promotes the growth of corresponding cancer cells
In the CHRYSALIS trial, 19 NSCLC patients with METex14 mutations received Rybrevant treatment
.
The primary endpoint of the trial is the overall response rate (ORR)
In terms of safety, most treatment-related adverse events (AE) are grade 1-2
.
In the trial, 3 patients (16%) observed treatment-related grade 3 AEs, including dyspnea (N=1), hypoalbuminemia (N=1), and skin rash (N=1)
Reference materials:
[1] Janssen Presents Phase 1 Results for Rybrevant™ (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations.
(The original text has been deleted)
